GovChime
Notice ID: 0ed1ab6f57c84ff8b98df9ed5913cf7bSpecial Notice

Notice of Intent to Use Other than Full and Open Competition

Archived on September 25, 2024. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
4:00 PM UTC−04:00
Posted
August 26, 2024
Notice type
Special Notice
NAICS
541714: Research and Development in Biotechnology (except Nanobiotechnology)
Agency
Department of Health and Human Services

Notice details

Last updated
Sep 25, 2026

Identifiers

Solicitation number
75A50120Q00001
Notice ID
0ed1ab6f57c84ff8b98df9ed5913cf7b

Description

The Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), Division of Contract Management & Acquisition (DCMA), and Office of the Biomedical Advanced Research and Development Authority (BARDA), has an immediate need to revise the requirements for the ongoing Phase 2b clinical studies due to FDA changes regarding the updated COVID-19 vaccine formula to be used, to include a safety lead-in cohort to the study, for the ongoing Phase IIb clinical trials in support of the development of second generation 2019 Novel Coronavirus (COVID-19) countermeasures. To support this requirement, the Government intends to award bilateral modifications on a sole source basis to increase the maximum ordering amounts for the following Clinical Trial Execution & Planning (CTPE) contracts: --Contract 75A50120D00016 with Allucent Government Services (formerly known as Pharm-Olam LLC) for Clinical Trial Planning and Execution will be modified to increase the maximum ordering amount by $150M from $400M to $550M. --Contract 75A50120D00017 with ICON Government and Public Health Solutions, Inc. (ICON) for Clinical Trial Planning and Execution will be modified to increase the maximum ordering amount by $150M from $400M to $550M. This sole source is based under the authority of 41 United States Code (U.S.C.) 3304(a)(1) as set forth in Federal Acquisition Regulation (FAR) 6.302-1, Only One Responsible Source and No Other Supplies or Services will satisfy Agency Requirements. This notice of intent to award a sole source contract will be posted for fifteen (15) calendar days to verify that no other sources can meet this requirement given only one responsible source and no other supplies or services will satisfy the Government requirements. This fifteen (15) calendar day notice shall expire on September 10, 2024, 4:00 PM Eastern Standard Time. If no credible responses to the intent to sole source are received by the Government, bilateral modifications will be awarded to increase the maximum ordering amounts for the following CTPE contracts: --Contract 75A50120D00016 with Allucent Government Services (formerly known as Pharm-Olam LLC) for Clinical Trial Planning and Execution will be modified to increase the maximum ordering amount by $150M from $400M to $550M. --Contract 75A50120D00017 with ICON Government and Public Health Solutions, Inc. (ICON) for Clinical Trial Planning and Execution will be modified to increase the maximum ordering amount by $150M from $400M to $550M. In accordance with FAR Part 6.305, 14 days after the award of these bilateral contract modifications, the Government will amend the intent to sole source by posting the redacted Justification and Approval (J&A) for 30 days. This notice of intent is not a request for competitive proposals. Interested individuals may identify their interest and capability to respond to the requirement by submitting in writing their name, address, telephone number, email, and a statement regarding capability to provide the specified efforts above. Responses shall be limited to ten (10) pages or less, including all attachments. Interested parties will be considered only if they respond to this notice with clear and convincing evidence that competition would be advantageous to the Government, would not be cost or time prohibitive, and that they can meet the revised requirements due to FDA changes regarding the updated COVID-19 vaccine formula to be used, to include a safety lead-in cohort to the study for the ongoing Phase IIb clinical trials in support of the development of second generation 2019 Novel Coronavirus (COVID-19) countermeasures. All capability statements, proposals, or quotes received prior to September 09, 2024, 4:00 PM Eastern Standard Time will be considered by the Government. The Government will not be responsible for any costs incurred by responding to this notice. The Government will notify parties of the outcome of any capability statements. A determination by the Government not to compete the proposed contract modifications based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Anticipated Award Date and Period of Performance: The two CTPE Indefinite Delivery Indefinite Quantity (IDIQ) contracts include a two-year base period and 3 one-year option periods. If all options are exercised, the contract period performance will end on 9/27/2025. Performance Schedule: The two CTPE IDIQ contracts include a two-year base period and 3 one-year option periods. If all options are exercised, the contract period performance will end on 9/27/2025. Contract type: The two CTPE contracts are Indefinite Delivery Indefinite Quantity (IDIQ) type contracts. Estimated award amount: --Contract 75A50120D00016 with Allucent (formerly known as Pharm-Olam LLC) for Clinical Trial Planning and Execution will be modified to increase the maximum ordering amount by $150M from $400M to $550M. --Contract 75A50120D00017 with ICON Government and Public Health Solutions, Inc. (ICON) for Clinical Trial Planning and Execution will be modified to increase the maximum ordering amount by $150M from $400M to $550M. Background: The Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), Division of Contract Management & Acquisition (DCMA), and Office of the Biomedical Advanced Research and Development Authority (BARDA), has an immediate need to revise the requirements for the ongoing Phase 2b studies due to FDA changes regarding the updated COVID-19 vaccine formula to be used, to include a safety lead-in cohort to the study, for ongoing Phase IIb clinical trials in support of the development of second generation 2019 Novel Coronavirus (COVID-19) countermeasures. Contracting Office Address: Office of the Secretary, Administration for Strategic Preparedness and Response (ASPR), Division of Contracts Management and Acquisition (DCMA) on behalf of the Office of Biomedical Advanced Research and Development Authority (BARDA) 400 7th Street, SW, Washington, District of Columbia 20024 United States. Place of Performance: Allucent Government Services (US) LLC 1570631 2000 Centre Green Way, Suite 300 Cary, NC 27513-5756 ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC 731 Arbor Way, Suite 100 Blue Bell, PA 19422-1987

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Documents

No documents available.

Lifecycle

Solicitation:75A50120Q00001
  1. Special NoticeCurrentAug 26, 2024

    Notice of Intent to Use Other than Full and Open Competition

    Notice 0ed1ab6f57c84ff8b98df9ed5913cf7b on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
BARDA seeks Contractor(s) to support the continuation of the Vaccine Medical Counermeasures (MCM's) for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods. Mandatory Qualification Requirements: To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by: 1. Holding a U.S. influenza vaccine license; or 2. Have developed an influenza vaccine as evidenced by: a. Submission of a Biologics License Application (BLA) for seasonal or pandemic influenza vaccine Please see full solicitation details and proposal submission instructions detailed in attachments 01-21 of this notice.
-Solicitation11/20/2026
The Advanced Research Projects Agency for Health (ARPA-H) Emerging Health Innovators (EHI) aims to or seeks to ensure ARPA-H identifies and engages early career investigators. To achieve this goal, ARPA-H is soliciting proposals from these researchers and innovators and their organizations to develop cutting-edge biomedical, health, and community-engaged research and innovation. ARPA-H anticipates multiple Other Transaction awards resulting from this announcement Amendment 1: This amendment clarifies the number of submissions that may be submitted by each offeror. See section 2.4 of the ISO. It also updates the solution summary cover sheet and the FAQ. Amendment 2: This amendment uploads two question and answer documents.
-Solicitation02/10/2027
The Advanced Research Projects Agency for Health (ARPA-H) posts this Special Notice in support of its Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) Program. Interested parties are invited to review the attached Notice related to an informational webinar on 15 OCT 2026 and a 2-day Proposers’ Day on 6 and 9 NOV 2026 in support of SURPASS. For more information related to the SURPASS opportunity, see solicitation ARPA-H-SOL-26-164. All questions related to SURPASS should be submitted to SURPASS@ARPA-H.GOV.
-Special Notice10/12/2026
The Advanced Research Projects Agency for Health (ARPA-H) posts this solicitation in support of its Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) Program. ARPA-H anticipates multiple Other Transaction Agreement awards will result from this opportunity. Interested parties are invited to review the attached Solicitation (ARPA-H-SOL-26-164) and associated attachments. As detailed in Special Notice ARPA-H-SN-26-164, ARPA-H will host an informational webinar on 15 OCT 2026 and a 2-day Proposers’ Day on 6 and 9 NOV 2026 in support of SURPASS. All questions related to SURPASS should be submitted to SURPASS@ARPA-H.GOV.
-Solicitation11/30/2026
Amendment 01: The Proposers' Day has been updated to October 16th, 2026. The Advanced Research Projects Agency for Health (ARPA-H) is posting this Innovative Solutions Opening (ISO) in support of the UNifying Imaging with QUantum Entanglement (UNIQUE) Program. ARPA-H anticipates that multiple Other Transaction (OT) Agreements will result from this announcement. Interested parties are invited to review the attached UNIQUE-ISO-ARPA-H-SOL-26-162 and UNIQUE ISO Attachments. Additionally, proposers are encouraged to review the separate Special Notice, ARPA-H-SN-26-162, for information regarding the UNIQUE Proposers’ Day. Special Notice, ARPA-H-SN-26-162, is an independent announcement and is not attached to this ISO announcement. All questions submitted to the ISO will be compiled and addressed. All answers will be posted to the UNIQUE Frequently Asked Questions (FAQ) page. Potential proposers are encouraged to monitor the FAQs page regularly for the latest information and updates: https://arpa-h.gov/explore-funding/programs/unique/faqs
-Solicitation12/15/2026

Additional Details

Solicitation Number

75A50120Q00001

Archive Date

Sep 25, 2024

Office Address

Washington, DC, 20201, US